Free Trial
NASDAQ:CLLS

Cellectis (CLLS) Stock Price, News & Analysis

Cellectis logo
$1.58 -0.07 (-3.94%)
As of 07/3/2025 03:11 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Cellectis Stock (NASDAQ:CLLS)

Key Stats

Today's Range
$1.57
$1.65
50-Day Range
$1.33
$1.65
52-Week Range
$1.10
$2.43
Volume
37,406 shs
Average Volume
143,032 shs
Market Capitalization
$88.09 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00
Consensus Rating
Buy

Company Overview

Cellectis Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
62nd Percentile Overall Score

CLLS MarketRank™: 

Cellectis scored higher than 62% of companies evaluated by MarketBeat, and ranked 1588th out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Cellectis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Cellectis has only been the subject of 1 research reports in the past 90 days.

  • Read more about Cellectis' stock forecast and price target.
  • Earnings Growth

    Earnings for Cellectis are expected to decrease in the coming year, from ($0.46) to ($0.52) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cellectis is -1.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cellectis is -1.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Cellectis has a P/B Ratio of 0.67. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Cellectis' valuation and earnings.
  • Percentage of Shares Shorted

    0.46% of the float of Cellectis has been sold short.
  • Short Interest Ratio / Days to Cover

    Cellectis has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cellectis has recently increased by 9.42%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Cellectis does not currently pay a dividend.

  • Dividend Growth

    Cellectis does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.46% of the float of Cellectis has been sold short.
  • Short Interest Ratio / Days to Cover

    Cellectis has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cellectis has recently increased by 9.42%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Cellectis has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Cellectis this week, compared to 1 article on an average week.
  • MarketBeat Follows

    1 people have added Cellectis to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Cellectis insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    16.41% of the stock of Cellectis is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    63.90% of the stock of Cellectis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Cellectis' insider trading history.
Receive CLLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cellectis and its competitors with MarketBeat's FREE daily newsletter.

CLLS Stock News Headlines

Cellectis files $200M mixed shelf offering
Presidential Bombshell: $150T Resource to Be Released as soon as this Summer?
Something extraordinary is happening in Washington. For the first time in over a century, a sitting President could release a national treasure that's been tied up in red tape, for generations. I'm talking about a $150 trillion American asset that's scattered across all 50 states. While the mainstream media focuses on political theater, this story is quietly developing behind closed doors.
See More Headlines

CLLS Stock Analysis - Frequently Asked Questions

Cellectis' stock was trading at $1.80 at the start of the year. Since then, CLLS shares have decreased by 11.9% and is now trading at $1.5850.

Cellectis S.A. (NASDAQ:CLLS) issued its earnings results on Monday, May, 12th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.15) by $0.03. The biotechnology company had revenue of $12.03 million for the quarter, compared to the consensus estimate of $12.71 million. Cellectis had a negative trailing twelve-month return on equity of 62.55% and a negative net margin of 114.82%.

Cellectis (CLLS) raised $129 million in an initial public offering on Wednesday, March 25th 2015. The company issued 3,500,000 shares at $36.83 per share. BofA Merrill Lynch, Jefferies and Piper Jaffray served as the underwriters for the IPO and Oppenheimer was co-manager.

Shares of CLLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cellectis investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), SPDR Dow Jones Industrial Average ETF Trust (DIA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU) and Alibaba Group (BABA).

Company Calendar

Last Earnings
5/12/2025
Today
7/04/2025
Next Earnings (Estimated)
8/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CLLS
Employees
290
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.00
High Stock Price Target
$4.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+152.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$36.76 million
Net Margins
-114.82%
Pretax Margin
-82.79%

Debt

Sales & Book Value

Annual Sales
$49.22 million
Price / Cash Flow
N/A
Book Value
$2.36 per share
Price / Book
0.67

Miscellaneous

Free Float
46,463,000
Market Cap
$88.09 million
Optionable
Optionable
Beta
2.91

Social Links

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:CLLS) was last updated on 7/4/2025 by MarketBeat.com Staff
From Our Partners